Post Operative Infection and Increased Survival in Osteosarcoma Patients: Are They Associated?
- 490 Downloads
Despite neo-adjuvant chemotherapy osteosarcomas having significant mortality, recent studies have shown survival advantages following infections for some tumour types. This study investigates the effect of post-operative infection in patients treated for osteosarcoma using endoprosthetic replacement and neo-adjuvant chemotherapy.
Material and Methods
A consecutive series of 547 patients underwent surgery between 1981 and 2001 for osteosarcoma. Patients were excluded from the study if over 60 years old at diagnosis (n = 14) as they would not routinely receive chemotherapy. Studies showed that 70% of deep infections occur within one year from reconstruction. Therefore landmark analysis was performed; all patients infected after 12 months of reconstruction were excluded (15 patients, 2.7%) and those who died within 12 months from diagnosis due to metastases were excluded (105 patients, 19.2%), leaving 412 patients. Any survival advantage of early infection was analysed by Kaplan-Meier survival analysis from this landmark point.
Overall population survival was 65% at 10 years after landmarking. There were 41 patients (10%) who developed an infection within one year of implantation. These patients had significantly better survival (p = 0.017). The 10-year survival for patients with osteosarcoma with infection was 84.5% compared to 62.3% in the non-infected group after landmarking. There was no significant difference in the percentage post-chemotherapy specimen necrosis between the two groups (p = 0.36). Infection was an independent prognostic factor on cox regression analysis.
There was evidence for increased survival after deep post-operative infection in osteosarcoma patients, in keeping with other research. The authors feel this warrants further investigation.
KeywordsOsteosarcoma Deep Infection Infected Group Isolate Limb Perfusion Landmark Point
- 21.American Cancer Society. Guide to complementary & alternative cancer methods. Atlanta: American Cancer Society Inc.; 2000Google Scholar
- 22.Shear MJ, Turner FC. Chemical treatment of tumours; isolation of hemorrhagic-producing fraction from Serratia marcescens (Bacillus prodigious) culture filtrate. J Natl Cancer Inst 1943; 4:81–7Google Scholar
- 23.Algire GH, Legallais FY, Park HD. Vascular reactions of normaland malignant tissues in vivo. II. The vascular reaction of normal and neoplastic tissues of mice to a bacterial polysaccharide from Serratia marcescens (Bacillus prodigious) culture filtrates. J Natl Cancer Inst 1947; 8:53–62Google Scholar
- 33.Krone B, Kolmel KF, Grange JM, Mastrangelo G, Hez BM, Botev IN, Niin M, Seebacher C, Lambert D, Shafir R, Kokoschka EM, Kleeberg UR, Gefeller O, Pfahlberg A. Impact of vaccinations and infectious diseases on the risk of melanoma – evaluation of an EORTC case control study. Eur J Cancer. 2004; 39(16):2372–8CrossRefGoogle Scholar
- 51.Pritchard-Jones K, Spendlove I, Wilton C, Whelan J, Weeden S, Lewis I, Hale J, Douglas C, Pagonis C, Campbell B, Alvarez P, Halbert G, Durrant LG. Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma. Br J Cancer 2005; 92(8):1358–65PubMedCrossRefGoogle Scholar
- 54.Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML,Conrad E, Ferguson W, Gebhardt M, Goorin AM, Harris MB, Healey J, Huvos A, Link M, Montebello J, Nadel H, Nieder M, Sato J, Siegal G, Weiner M, Wells R, Wold L, Womer R, Grier H. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005; 23(9):2004–11PubMedCrossRefGoogle Scholar
- 56.Kurzman ID, MacEwen EG, Rosenthal RC, Fox LE, Keller ET, Helfand SC, Vail DM, Dubielzig RR, Madewell BR, Rodriguez CO Jr, et al. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clin Cancer Res 1995; 1(12):1595–601PubMedGoogle Scholar